ANL 11.45 Increased By ▲ 0.33 (2.97%)
ASC 9.80 Increased By ▲ 0.15 (1.55%)
ASL 11.35 Increased By ▲ 0.09 (0.8%)
AVN 78.30 Increased By ▲ 3.89 (5.23%)
BOP 5.83 Increased By ▲ 0.06 (1.04%)
CNERGY 5.54 Increased By ▲ 0.26 (4.92%)
FFL 6.97 Increased By ▲ 0.06 (0.87%)
FNEL 6.15 Increased By ▲ 0.10 (1.65%)
GGGL 12.15 Increased By ▲ 0.21 (1.76%)
GGL 16.82 Increased By ▲ 0.69 (4.28%)
GTECH 9.65 Increased By ▲ 0.54 (5.93%)
HUMNL 6.65 Increased By ▲ 0.11 (1.68%)
KEL 2.56 Increased By ▲ 0.04 (1.59%)
KOSM 3.00 Decreased By ▼ -0.01 (-0.33%)
MLCF 27.25 Increased By ▲ 0.95 (3.61%)
PACE 3.10 Increased By ▲ 0.06 (1.97%)
PIBTL 6.11 Increased By ▲ 0.12 (2%)
PRL 17.88 Increased By ▲ 1.28 (7.71%)
PTC 8.15 Increased By ▲ 0.65 (8.67%)
SILK 1.43 Increased By ▲ 0.06 (4.38%)
SNGP 26.09 Increased By ▲ 0.29 (1.12%)
TELE 11.76 Increased By ▲ 1.01 (9.4%)
TPL 9.89 Increased By ▲ 0.59 (6.34%)
TPLP 17.68 Increased By ▲ 1.03 (6.19%)
TREET 30.10 Increased By ▲ 1.20 (4.15%)
TRG 81.68 Increased By ▲ 3.28 (4.18%)
UNITY 23.27 Increased By ▲ 1.06 (4.77%)
WAVES 13.50 Increased By ▲ 0.55 (4.25%)
WTL 1.60 Increased By ▲ 0.06 (3.9%)
YOUW 5.10 No Change ▼ 0.00 (0%)
BR100 4,233 Increased By 69.5 (1.67%)
BR30 15,486 Increased By 584.9 (3.93%)
KSE100 42,542 Increased By 529.1 (1.26%)
KSE30 16,143 Increased By 230 (1.45%)
World

Britain has secured 50mn doses of vaccines for new variants: Hancock

  • He said Britain had entered into a partnership with the manufacturer CureVac to develop vaccines that could be quickly adapted as new strains were identified.
09 Feb, 2021

LONDON: Britain has agreed a initial supply of 50 million doses of vaccines for new variants, Heath Secretary Matt Hancock said on Monday, although he added that evidence showed the shots already being deployed had some effect against the mutations.

"The evidence is that the existing vaccines have some effect against new variants, particularly preventing serious illness and mortality," Hancock told a news briefing on Monday.

He said Britain had entered into a partnership with the manufacturer CureVac to develop vaccines that could be quickly adapted as new strains were identified.

"We've agreed an initial supply of 50 million doses to add to the 400 million doses that are already in our vaccine portfolio," he said.

Comments

Comments are closed.